[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Region Skane\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":695},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,90,0,25,[9,48,82,108,130,153,174,205,235,271,308,337,361,383,406,440,467,495,517,546,569,594,621,643,670],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100540311","stroke-alarm-efficacy-trial-100540311",false,"NCT06315192","Stroke Alarm Efficacy Trial","StrokeAlarmEFF","INCLUSION CRITERIA\n\n1. Age 50 years or older\n2. Modified Rankin scale of 0-2.\n3. Diagnosed with either:\n\n   A. Recent\\* transient ischemic attack (TIA, G45.9), AND:\n   * ABCD2 score of ≥6, OR:\n   * Atrial fibrillation OR:\n   * Large artery atherosclerosis\\*\\*.\n\n   B. Recent\\* acute ischemic stroke (I63), AND:\n\n   • Atrial fibrillation, OR:\n   * Large artery atherosclerosis\\*\\*. C. Atrial fibrillation\u002Fflutter (I48), AND\n   * None, or reduced dose of, oral anticoagulation medication\\*\\*\\*, AND\n   * CHA2DS2-VASC score ≥4.\n\n   D. Recent\\* intracerebral hemorrhage (I61.9), AND:\n\n   • Atrial fibrillation.\n4. The patient has received the required information about the study and agrees in writing to participate.\n5. Smartphone user since at least 1 year.\n\n   * Within the last 2 weeks \\*\\*Atherosclerosis in carotid, vertebral aortic arch or major intracerebral arteries according to CTA or ultrasound.\n\n     * Including all oral anticoagulation medication such as Warfarin and NOACs. Patients with reduced dose of a NOAC can be included, regardless if this is within the approved label, or if reduced dose is chosen off-label for other reasons. Treatment with antiplatelet medication is permissible.\n\nEXCLUSION CRITERIA\n\n1. Previous inclusion in this study.\n2. Arm motor deficit from any previous medical condition.\n3. Unable to give informed consent to participate in the study.\n4. Does not master any of the languages available within the Stroke Alarm smartphone app in speech and writing.\n5. Does not have access to a Stroke Alarm compatible smartphone.\n6. Deemed unable to handle the Stroke Alarm smartphone app, or participate in planned follow-up within the framework of the study due to other diseases or circumstances.\n7. Does not want to participate.","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","INTERVENTIONAL",[24],"NA","The aim of this study is to test the efficacy of the CE-marked wearable system Stroke Alarm to identify the onset of a stroke with unilateral arm motor deficit within 3 hours of onset.\n\nThis is a multicenter, prospective observational single-arm trial with a registry-based propensity matched control population.\n\nA total of 500 patients will be included in the trial. An interim analysis will determine if the stroke onset frequency is sufficient to determine the main outcome. Should the number of stroke events differ from what is expected at interim analysis, study enrollment will continue to increase cohort size.\n\nPatients who meet the criteria for participation will, after signing consent, be included and receive the Stroke Alarm bracelets that are used for 3 months. Study data will be collected as baseline at inclusion, at follow-up 3 months after inclusion and by using national Swedish registry data after completion of the study.\n\nPatients with elevated stroke risk according assessed by presence of specific criteria associated with elevated risk caused by:\n\n1. recent TIA with an ABCD2 score of ≥6, large artery atherosclerosis or atrial fibrillation, OR\n2. recent ischemic stroke with large artery atherosclerosis or atrial fibrillation, without persisting arm motor deficit, OR\n3. atrial fibrillation with an CHA2DS2-Vasc score ≥ 4 without adequate anticoagulation OR\n4. recent hemorrhagic stroke with atrial fibrillation, without persisting arm motor deficit The combined efficacy goal is at least 60% sensitivity for Stroke Alarm b of stroke with unilateral arm motor deficit within 3 hours of onset (with a 95% confidence interval above 30%) and a specificity of at least 80% using a clinical stroke diagnosis as gold standard.\n\nA control population matched for calendar year, age (± 5 years), sex, healthcare region, baseline stroke severity according to the National Institutes of Health Stroke Scale (NIHSS, ± 5 points), unilateral arm motor deficit (NIHSS item 5a\u002F5b 1-4), presence of neglect\u002Finattention (NIHSS item 11 1-2), atrial fibrillation, cohabitation status and pre-stroke functional level twill be identified in the Swedish national stroke registry, Riksstroke, and used for comparison.",[27,28,29],"Stroke Acute","Atrial Fibrillation","TIA",[31,32,33,34],"Stroke","wearable","indication","sensor","RECRUITING","2026-06-29",{"date":38,"type":39},"2026-06-30","ACTUAL",{"date":41,"type":39},"2024-09-05",{"date":43,"type":21},"2027-12-31",{"name":45,"class":46},"Region Skane","OTHER",10,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":4},"100645168","recovery-with-virtual-reality-for-stress-and-pain-100645168","NCT07679022","Recovery With Virtual Reality for Stress and Pain","Recovery With Virtual Reality for Stress & Pain (ReVRS)","ReVRS","Inclusion Criteria:\n\n* Adults aged 18 years or older.\n* Scheduled to undergo elective gynecological surgery according to the study protocol at a participating center where virtual reality can be provided.\n* Able and willing to provide informed consent for study participation, 1:1 randomization, and use of virtual reality.\n\nExclusion Criteria:\n\n* Increased risk of adverse effects related to virtual reality, including pronounced motion sickness, claustrophobia, or photosensitive epilepsy.\n* Active substance use disorder or active misuse of alcohol or illicit drugs.\n* Severe chronic pain and\u002For regular preoperative opioid treatment, as defined in the study protocol.",{"count":57,"type":21},140,[24],"This randomized controlled trial will evaluate whether a brief preoperative virtual reality intervention reduces anxiety and improves early recovery in adults undergoing elective gynecological surgery. Approximately 140 participants will be randomly assigned in a 1:1 ratio to either virtual reality in addition to usual care or usual care alone. The virtual reality intervention will consist of approximately 10-20 minutes of an immersive relaxation experience before surgery. The primary outcome is the change in preoperative anxiety measured before and after the intervention. Secondary outcomes include postoperative quality of recovery, pain, opioid consumption, postoperative nausea and vomiting, and early recovery-related healthcare outcomes.",[61,62,63],"Preoperative Anxiety","Postoperative Pain","Postoperative Recovery",[65,66,67,68,69,61,62,70,71,72],"Virtual Reality","Perioperative Care","Gynecologic Surgery","Quality of Recovery","QoR-15","Opioid Consumption","Postoperative Nausea and Vomiting","Nonpharmacologic Intervention","NOT_YET_RECRUITING","2026-06-25",{"date":76,"type":39},"2026-07-01",{"date":78,"type":21},"2026-09-30",{"date":80,"type":21},"2029-02-28",{"name":45,"class":46},{"id":83,"slug":84,"hasResults":12,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":97,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100611846","clustervap-multicentre-proteomic-endotyping-of-ventilator-associated-pneumonia-100611846","NCT07245888","ClusterVAP: Multicentre Proteomic Endotyping of Ventilator-associated Pneumonia","Endotyping of Ventilator-associated Pneumonia With Proteomics on Bronchoalveolar Lavage for Improved Diagnosis, the ClusterVAP Study","ClusterVAP","Inclusion Criteria:\n\nAdult patients (≥18 years) admitted to an intensive care unit (ICU). Receiving invasive mechanical ventilation. Undergoing bronchoalveolar lavage (BAL) or mini-BAL on clinical indication for suspected lower respiratory tract infection.\n\nNew or worsening clinical signs compatible with lower respiratory tract infection within the preceding 24 hours, defined as the treating clinician's suspicion plus at least one of:\n\nBody temperature \\>38 °C or \\\u003C36 °C. Visually purulent tracheal secretions. Signs of reduced oxygenation (e.g., increased FiO₂ and\u002For decreased arterial pO₂, increased positive end-expiratory pressure or driving pressure).\n\nRequest for chest radiograph to investigate infection or new infiltrate. Initiation of antibiotic therapy targeting lower respiratory tract infection.\n\nExclusion Criteria:\n\nBAL or mini-BAL performed solely for screening without suspicion of infection. Concurrent enrolment in the VAPmarkers study (reserved for external validation).\n\nAge \\\u003C18 years. Any condition that, in the opinion of the investigator, would preclude safe participation or confound study objectives.",{"count":91,"type":21},400,"OBSERVATIONAL","Ventilator-associated pneumonia (VAP) is a common and serious infection in patients receiving mechanical ventilation in intensive care units. Current diagnostic methods are imprecise, leading to unnecessary antibiotic use and delayed treatment. The ClusterVAP study aims to identify biologically and clinically distinct subgroups of patients with suspected VAP by analyzing proteins in bronchoalveolar lavage (BAL) fluid using advanced proteomic techniques. This multicentre observational study will enroll approximately 400 adult patients from intensive care units in Sweden, France, Portugal, Denmark, and the United Kingdom. BAL or mini-BAL samples collected for clinical reasons will be analyzed to define \"pneumoclusters\" and explore their association with patient outcomes. The study will also identify candidate biomarkers that could support future diagnostic tools. No experimental treatments are given; all patients receive standard care. Results may improve diagnostic accuracy and guide personalized treatment strategies for critically ill patients.",[95,96],"Ventilator Acquired Pneumonia","Mechanical Ventilation Complication",[98,99,100],"VAP","endotyping","mini-BAL",{"date":38,"type":39},{"date":103,"type":39},"2026-05-01",{"date":105,"type":21},"2027-12",{"name":45,"class":46},4,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":118,"conditions":119,"keywords":121,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},"100448259","biomarkers-for-ventilator-associated-pneumonia-100448259","NCT05117125","Biomarkers for Ventilator-associated Pneumonia","Biomarkers for Prediction of and Diagnosis of Ventilator-associated Pneumonia","VAPmarkers","Inclusion Criteria:\n\n* Admission to an intensive care unit\n* Intubation within last 24 hours\n* Anticipated mechanical ventilation of at least 48 hours\n\nExclusion Criteria:\n\n* FiO2 above 70% or PEEP above 15\n* Severe coagulopathy (spontaneous PK(INR) \\>1.8 or thrombocytes \\\u003C50). Prophylaxis treatment dose of LMWH or factor Xa inhibitors\u002FNOAC is not an exclusion criteria. If higher doses of these substances are administered, the responsible clinician should be consulted before sample collection.\n* Ongoing infection of the lungs at admission to the ICU.\n* Severely elevated or instable intracranial pressure.",{"count":117,"type":21},1000,"The purpose of this study is to evaluate different peptide biomarkers, variations in the microbiome and patterns in the bacterial transcriptome as prognostic or diagnostic biomarkers of VAP.",[120],"Pneumonia, Ventilator-Associated",[98],{"date":123,"type":39},"2026-06-26",{"date":125,"type":39},"2021-10-15",{"date":127,"type":21},"2028-12-31",{"name":45,"class":46},5,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":137,"sex":17,"minAge":138,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},"100642231","effect-of-the-digital-livsstilsverktyget-in-conjunction-with-a-large-language-model-on-the-prevention-of-type-2-diabetes-100642231","NCT07659535","Effect of the Digital Livsstilsverktyget in Conjunction With a Large Language Model on the Prevention of Type 2 Diabetes","Personalized Study With the Lifestyle Tool","Inclusion criteria\n\n* Informed consent\n* Age above 35 years\n* Access to Internet and mobile or computer device\n\nExclusion criteria\n\n* diabetes mellitus\n* conditions or treatments that in the judgement of the Investigator could affect the study evaluation\n* connection with the study team, funders, authorities, universities or other public or private bodies in such a way that specific interests in the study outcomes could be suspected.\n* living outside of Sweden\n* inability to read and write in Swedish",true,"35 Years",{"count":140,"type":21},40000,[24],"The overall aim of the study is to investigate the incidence of type 2 diabetes in individuals who have access to a digital intervention tool as compared with randomized controls during three years. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. Users get access to expert-written information about relevant health topics and interact with an LLM to promote reflection on the information.",[144],"Type 2 Diabetes","2026-06-22",{"date":74,"type":39},{"date":148,"type":21},"2026-06-15",{"date":150,"type":21},"2030-12-31",{"name":45,"class":46},1,{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":4,"eligibilityCriteria":159,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":160,"enrollmentInfo":161,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":4},"100619907","inpatient-care-of-patients-with-difficult-to-treat-anorexia-nervosa---factors-affecting-treatment-outcome-100619907","NCT07350720","Inpatient Care of Patients With Difficult to Treat Anorexia Nervosa - Factors Affecting Treatment Outcome.","Inpatient Care of Patients With Difficult to Treat Eating Disorders - What Affects Treatment Outcome?","Inclusion Criteria:\n\n* Anorexia Nervosa diagnosis (ICD F50.0)\n* Admitted to inpatient care at department 5 at Region Skåne Eating Disorders Center\n\nExclusion Criteria:\n\n* Confidential identity\n* Inability to read or write in Swedish or English\n* Condition or treatment that, according to the study team, makes participation in the study inappropriate","64 Years",{"count":162,"type":21},100,"The overall aim of the project is to investigate factors that may influence treatment outcomes in people with difficult-to-treat anorexia nervosa who are enrolled in inpatient care at the Region Skåne Eating Disorders Centre in Lund. Treatment expectations, sense of autonomy, and patient participation, will be investigated, as well as caregivers' attitudes towards, and experiences of working with, autonomy and patient participation in the inpatient setting. The research project is expected to contribute to increased knowledge about the treatment of difficult-to-treat anorexia nervosa, and what part patient participation and autonomy may play when treating severe eating disorders. The overall objectives of the research program are:\n\n1. To contribute to increased knowledge about factors that influence the treatment of people with difficult-to-treat anorexia nervosa\n2. To highlight the role of autonomy and patient participation in inpatient care of severe eating disorders\n3. To use the research results for clinical improvement work at Region Skåne Eating Disorders Center",[165,166],"Eating Disorders","Anorexia Nervosa",{"date":168,"type":39},"2026-06-16",{"date":170,"type":21},"2026-09",{"date":172,"type":21},"2029-12",{"name":45,"class":46},{"id":175,"slug":176,"hasResults":12,"nctId":177,"briefTitle":178,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":183,"conditions":184,"keywords":191,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":152},"100454296","acute-acute-surgical-care--risk-factors-and-outcomes-for-patients-in-need-of-acute-surgical-care-100454296","NCT05195697","ACUTE-Acute Surgical Care- Risk Factors and Outcomes for Patients in Need of Acute Surgical Care","ACUTE","Inclusion Criteria: Patients admitted to Skåne University hospital in need of acute surgical care -\n\nExclusion Criteria: Below 18 years old\n\n\\-",{"count":182,"type":21},3000,"Observational retrospective study of patients in need of acute surgical care admitted to Skåne University Hospital between 2009 and 2019.",[185,186,187,188,189,190],"Risk Factors","Complication of Surgical Procedure","Complication of Treatment","Complication of Anesthesia","Long Term Effects After Emergency Surgery","Long Term Effects After GI Bleeding",[192,193,194,195,196,197],"Emergency surgery","Acute surgery","Complications","Risk factors","Frailty","Ageing",{"date":199,"type":39},"2026-06-17",{"date":201,"type":39},"2020-01-01",{"date":203,"type":21},"2030-12",{"name":45,"class":46},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":152},"100643524","phase-4-comparing-intraoperative-indocyanine-green-fluorescence-imaging-with-standard-clinical-assessment-for-flap-perfusion-in-head-and-neck-reconstruction-vision-trial-100643524","NCT07635420","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)","Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction: A Randomised Controlled Trial (VISION Trial)","VISION","Inclusion Criteria:\n\n* Age ≥18 years at the time of inclusion\n* Scheduled to undergo microvascular free flap reconstruction as part of oncologic, trauma, or benign surgery in the head and neck area\n* Ability to understand study information and provide written informed consent\n\nExclusion Criteria:\n\n* Known allergy to indocyanine green or iodine\n* Severe hepatic or renal impairment\n* Confirmed or suspected pregnancy\n* Breastfeeding",{"count":214,"type":21},244,[216],"PHASE4","This is a prospective multicentre randomised controlled trial evaluating whether intraoperative indocyanine green (ICG) fluorescence angiography improves outcomes in head and neck free flap reconstruction compared with standard clinical assessment of flap perfusion. Adult patients undergoing microvascular free flap reconstruction for oncologic, trauma, or benign head and neck defects will be randomised to either intraoperative ICG angiography or conventional clinical perfusion assessment. The primary outcome is partial flap loss requiring intervention within 30 days after surgery. Secondary outcomes include total flap loss, flap-related re-exploration, flap salvage, and postoperative complications.",[219,220,221,222,223,224,225,226],"Head and Neck Cancer (H&N)","Free Tissue Flaps","Free Flap","Free Flap Evaluation","Indocyanine Green","Indocyanine Green (ICG)","Microsurgery","Randomised Controlled Trial","2026-06-08",{"date":229,"type":39},"2026-06-09",{"date":231,"type":21},"2026-10-01",{"date":233,"type":21},"2029-08-01",{"name":45,"class":46},{"id":236,"slug":237,"hasResults":12,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":22,"phases":245,"briefSummary":246,"conditions":247,"keywords":260,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":152},"100596071","negative-pressure-wound-therapy-for-split-thickness-skin-grafting-to-the-lower-leg-after-excision-of-skin-tumour-a-multicentre-randomised-study-100596071","NCT07040683","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: A Multicentre Randomised Study","Negative Pressure Wound Therapy for Split Thickness Skin Grafting to the Lower Leg After Excision of Skin Tumour: The Legs Trial - A Multicentre Randomised Study","LEGS","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Undergoing excision of a skin tumour on the lower leg with planned coverage using split-thickness skin grafting (STSG)\n* Eligible procedures include primary excision, secondary excision, or extended excision performed at the same site as a previous tumour surgery\n* Ability to provide written informed consent\n* Ability to comply with postoperative instructions and follow-up visits\n\nExclusion Criteria:\n\n* Inability to follow postoperative instructions due to cognitive impairment, dementia, or significant language barriers\n* Inability to provide informed consent\n* Severe systemic illness, including:\n* Ongoing sepsis\n* Advanced heart failure\n* End-stage renal or liver disease\n* Active chemotherapy within the previous three months\n* Ongoing treatment with immunosuppressive medications, including:\n* Systemic corticosteroids (e.g., prednisone \\>20 mg\u002Fday or equivalent)\n* Calcineurin inhibitors (e.g., cyclosporine, tacrolimus)\n* Antimetabolites (e.g., methotrexate, azathioprine, mycophenolate mofetil)\n* mTOR inhibitors (e.g., sirolimus, everolimus)\n* Biologic therapies (e.g., rituximab, TNF inhibitors, IL-6 inhibitors, IL-1, IL-17, IL-23 inhibitors)\n* Targeted molecular therapies (e.g., JAK inhibitors such as tofacitinib, baricitinib)\n* Other immunosuppressive drugs\n* Previous radiation therapy to the surgical site\n* Presence of severe skin disease affecting the planned graft recipient site (e.g., advanced psoriasis)",{"count":244,"type":21},242,[24],"The goal of this clinical trial is to compare the effect of negative pressure wound therapy (NPWT) versus traditional dressings on the incidence of transplant infection in adult patients undergoing split-thickness skin grafting (STSG) to the lower leg following excision of a skin tumour. The main questions it aims to answer are:\n\nDoes NPWT reduce the incidence of transplant infection within three months after STSG?\n\nDoes NPWT improve secondary outcomes such as graft take, reduce reoperations, complications, and resource use?\n\nResearchers will compare patients treated with NPWT to patients treated with traditional dressings to see if NPWT results in lower infection rates and better clinical outcomes.\n\nParticipants will:\n\nUndergo excision of a skin tumour on the lower leg followed by STSG.\n\nBe randomized to receive either NPWT or traditional dressings applied over the graft.\n\nFollow a structured postoperative care and mobilisation schedule.\n\nAttend follow-up visits at day 5 and day 14 postoperatively and be monitored through medical record review up to three months after surgery.",[248,249,250,251,252,253,254,255,256,257,258,259],"Skin Transplantation","Skin Grafting","Split Thickness Skin Graft","Negative-Pressure Wound Therapy","Postoperative Complications","Surgical Wound Infection","Lower Extremity","Skin Cancer","Skin Tumour","Wound Healing","Bandages","Leg",[248,249,261,251,252,253,254,257,258,259,262,255],"Split Thickness","Skin Neoplasms","2026-05-27",{"date":265,"type":39},"2026-05-28",{"date":267,"type":39},"2025-11-01",{"date":269,"type":21},"2030-03-31",{"name":45,"class":46},{"id":272,"slug":273,"hasResults":12,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":277,"eligibilityCriteria":278,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":22,"phases":281,"briefSummary":282,"conditions":283,"keywords":288,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":307},"100549078","phase-4-international-care-bundle-evaluation-in-cerebral-hemorrhage-research-100549078","NCT06429332","International Care Bundle Evaluation in Cerebral Hemorrhage Research","International Care Bundle Evaluation in Cerebral Hemorrhage Research - a Batched Parallel Cluster-randomized Trial With a Baseline Period","I-CATCHER","Inclusion Criteria:\n\n* Adults (age ≥18 years)\n* Non-contrast computerized tomography (NCCT) imaging-verified diagnosis of spontaneous intracerebral haemorrhage\n* ≤24 hours from symptom onset or presumed symptom onset (last seen well)\n\nExclusion Criteria:\n\n* Previous care limitation\n* End-stage comorbidity with short life-expectancy (\\\u003C6 m; e.g. terminal cancer)\n* ICH caused by brain tumor or cerebral venous thrombosis\n* Clinical signs of brain herniation at first presentation (unresponsive patient with bilaterally fixed, maximally dilated pupils)\n* Pregnant women beyond 22 weeks gestation may only be included after thorough discussion with an obstetrician to determine risks vs benefit.",{"count":280,"type":21},3500,[216],"Spontaneous intracerebral haemorrhage (ICH) accounts for approximately 10-15% of all strokes but stands for 50% of stroke-related morbidity and mortality. Approximately half of all patients with ICH have a decreased level of consciousness at hospital admission. Despite this, intensive care and neurosurgical interventions are uncommon. A study conducted in low- and middle-income countries has demonstrated a beneficial effect of a treatment package consisting of early intensive blood pressure lowering, as well as the treatment of pyrexia and elevated blood glucose levels. The I-CATCHER team is now planning to conduct a similar study in Sweden and Australia, as well as in other high-income countries. The study has a clear focus on implementation, aiming to improve treatment and prognosis for patients with ICH within a few years. The purpose of I-CATCHER is to investigate whether a structured treatment package (Care Bundle) improves 3-month prognosis in patients with spontaneous ICH compared to standard care.",[284,285,286,31,287],"Intracerebral Hemorrhage","Intracerebral Haemorrhage","Intraventricular Hemorrhage","Cerebrovascular Disease",[289,290,291,292,293,294,295,296,297,298],"intracerebral hemorrhage","oral anticoagulant","blood pressure lowering","early intensive blood pressure lowering","care bundle","implementation study","reversal treatment","outcome","UW-mRS","Modified Rankin Scale","2026-05-20",{"date":301,"type":39},"2026-05-22",{"date":303,"type":39},"2025-01-07",{"date":305,"type":21},"2027-07",{"name":45,"class":46},54,{"id":309,"slug":310,"hasResults":12,"nctId":311,"briefTitle":312,"officialTitle":313,"acronym":314,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":316,"targetDuration":4,"studyType":22,"phases":318,"briefSummary":319,"conditions":320,"keywords":323,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":129},"100632283","the-study-tests-if-preoperative-dental-screening-is-superior-to-no-preoperative-dental-screening-in-improving-the-outcome-of-patients-undergoing-surgical-cardiac-valve-replacement-or-transcatheter-cardiac-valve-implantation-100632283","NCT07511673","The Study Tests if Preoperative Dental Screening is Superior to no Preoperative Dental Screening in Improving the Outcome of Patients Undergoing Surgical Cardiac Valve Replacement or Transcatheter Cardiac Valve Implantation.","SMILE: A Randomized Trial of Preoperative Dental Screening for the Prevention of Endocarditis, Reoperation or Death in Patients Undergoing Surgical or Transcatheter Cardiac Valve Intervention.","SMILE","Inclusion Criteria:\n\n* Age ≥18 years\n* Accepted for cardiac valve intervention\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Previous or ongoing infective endocarditis\n* Urgent surgery\n* Pain from loose tooth\u002Fteeth\n* Immunosuppressive therapy (excluding corticosteroids)\n* Inability to provide informed consent\n* Expected loss to follow-up",{"count":317,"type":21},1300,[24],"This randomized, multicenter, open-label trial evaluates whether preoperative dental screening improves outcomes in patients undergoing surgical or transcatheter cardiac valve intervention. Participants are randomized 1:1 to preoperative dental screening or no screening. The primary outcome is time to first occurrence of all-cause death, redo-intervention of the index valve, or definite infective endocarditis within 2 years. The study uses registry-based follow-up to ensure complete outcome ascertainment.",[321,322],"Infective Endocarditis (IE)","Heart Valve Disease",[324,325,326,327,328],"Dental screening","valve intervention","endocarditis","TAVI","valve surgery","2026-05-15",{"date":331,"type":39},"2026-05-19",{"date":333,"type":39},"2026-05-06",{"date":335,"type":21},"2036-12-01",{"name":45,"class":46},{"id":338,"slug":339,"hasResults":12,"nctId":340,"briefTitle":341,"officialTitle":341,"acronym":342,"eligibilityCriteria":343,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":345,"studyType":92,"phases":4,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":353,"lastUpdatePostDateStruct":354,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":152},"100629893","glow-gender-affirming-care-and-mental-health-a-longitudinal-study-on-quality-of-life-work-life-and-healthcare-outcomes-100629893","NCT07480590","GLOW: Gender-Affirming Care and Mental Health: A Longitudinal Study On Quality of Life, Work Life, and Healthcare Outcomes","GLOW","Inclusion Criteria:\n\n* All adults (18+) referred to the NHV clinic for gender dysphoria assessment in Region Skåne.\n\nExclusion Criteria:\n\n* Inability to read\u002Fwrite Swedish\n* Protected identity status",{"count":20,"type":21},"5 Years","Gender-Affirming Care and Mental Health (GLOW) investigates the psychological, medical, and social factors that influence the outcomes of gender-affirming care, as well as its impact on mental health, work capacity, and quality of life. Gender dysphoria is defined as the incongruence of a person's experienced gender and sex assigned at birth. In Sweden, the prevalence of gender dysphoria has increased significantly in recent decades. Still there is no consensus on the long-term outcomes ofgender-affirming care. 1. What are the baseline characteristics in individuals seeking gender-affirming care and do any of these predict outcomes of gender-affirmative care?2. Do individuals with gender dysphoria experience improved or reduced quality of life, gender congruence, or functional capacity after gender-affirming care?3. Does gender-affirming care reduce or increase psychiatric symptoms and self-concept clarity?4. What are the effects of gender-affirming care on mortality, work capacity, and healthcare resource utilization as compared to an age and gender matched control group?Data and MethodGLOW targets patients at the Gender Dysphoria Clinic, Region Skåne a National Highly Specialized Care unit (NHV). Mixed methods will be used to analyze data from national registries and self-reported assessments.The NHV status ensures standardized high-quality data collection and clinical follow-up, making this project a unique opportunity to evaluate the care given to individuals with gender dysphoria.Societal Relevance and Utility The growing demand for gender-affirming care underscores the need for research to identify the most effective interventions. The results may also help reduce stigma and improve social integration for individuals with genderdysphoria.GLOW is a longitudinal mixed-methods study based at the NHV Gender Dysphoria Clinic in Region Skåne. It includes registry-based, qualitative interviews and repeated self-report measures up to 5 years after baseline assessment. Quantitative analyses will include regression models and Bayesian methods.",[348],"Gender Dysphoria, Adult",[350,351,352],"gender dyshoria","longitudinal study","regsiter study","2026-05-13",{"date":355,"type":39},"2026-05-18",{"date":357,"type":39},"2025-12-01",{"date":359,"type":21},"2030-12-01",{"name":45,"class":46},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":371,"conditions":372,"keywords":374,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":378,"completionDateStruct":380,"leadSponsor":382,"locationsCount":152},"100546333","sense-of-security-with-access-to-palliative-outpatient-clinic-100546333","NCT06393569","Sense of Security With Access to Palliative Outpatient Clinic","Experience of Security Having Access to Specialized Palliative Care Clinic","Inclusion Criteria:\n\n\\- Patients admitted to included ASiH-unit\n\nExclusion Criteria:\n\n* Patients with cognitive impairment\n* Patients who cannot fill in a questionnaire in Swedish, Arabic or Serbo-Croatian.","120 Years",{"count":370,"type":21},200,"The aim of the study is to evaluate experience of security, accessibility, and avoidable utilization of health care services in patients who have had access to specialized palliative care clinic (SPCC) compared to those who have not, and to evaluate the relatives' experience of the care.",[373],"Cancer",[375],"Palliative care","2026-05-12",{"date":353,"type":39},{"date":379,"type":39},"2024-03-14",{"date":381,"type":21},"2029-03-14",{"name":45,"class":46},{"id":384,"slug":385,"hasResults":12,"nctId":386,"briefTitle":387,"officialTitle":388,"acronym":4,"eligibilityCriteria":389,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":390,"targetDuration":391,"studyType":92,"phases":4,"briefSummary":392,"conditions":393,"keywords":398,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":405,"locationsCount":152},"100492964","rehabilitation-and-recovery-for-persons-with-esophageal-or-gastric-cancer-100492964","NCT05698992","Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer","Rehabilitation and Recovery for Persons With Esophageal or Gastric Cancer - a Clinical Trial Evaluating and Implementing a Model for Evidence-based Cancer Rehabilitation","Inclusion Criteria:\n\n* over 18 years of age\n* esophageal or gastric cancer\n* living in Southern Sweden (Skåne)\n* are planned to undergo curative surgerytreatment at Skåne University Hospital.\n\nExclusion Criteria:\n\n* unable to communicate in the Swedish language\n* suffering from a cognitive impairment that poses a barrier for participating in the study.",{"count":162,"type":21},"15 Months","This study aims to develop and evaluate a model for systematic and evidence-based cancer rehabilitation for people with esophageal and gastric cancer to provide conditions for a better quality of life and fewer cancer-related symptoms.",[394,395,396,397],"Esophageal Cancer","Esophageal Neoplasms","Gastric Cancer","Stomach Neoplasm",[399,400],"Cancer rehabilitation","Recovery",{"date":329,"type":39},{"date":403,"type":39},"2023-02-27",{"date":43,"type":21},{"name":45,"class":46},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":412,"eligibilityCriteria":413,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":414,"targetDuration":416,"studyType":92,"phases":4,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":432,"startDateStruct":434,"completionDateStruct":436,"leadSponsor":438,"locationsCount":439},"100636368","pain-after-cardiac-arrest-and-resuscitation-paincare-100636368","NCT07564778","Pain After Cardiac Arrest and Resuscitation (PAINCARE)","Characterizing and Quantifying Pain After Cardiac Arrest and Resuscitation: Insights From the PAINCARE Substudy of the STEPCARE Trial","PAINCARE","Inclusion Criteria:\n\n* Out-of-hospital cardiac arrest\n* Adult, age 18 years or older\n* Spontaneous circulation without chest compressions for at least 20 minutes\n* Comatose, defined as not obeying verbal commands\n* Enrolled within 4 hours after return of spontaneous circulation\n\nExclusion Criteria:\n\n* Restrictions or limitations of care\n* On extracorporeal membrane oxygenation before randomization\n* Pregnancy\n* Previously randomized in the STEPCARE trial\n* Trauma or hemorrhage as the presumed cause of arrest\n* Suspected or confirmed intracranial hemorrhage",{"count":415,"type":21},300,"6 Months","The PAINCARE substudy is an observational cohort substudy nested within the international STEPCARE trial, which evaluates sedation, temperature, and mean arterial pressure strategies after out-of-hospital cardiac arrest. PAINCARE aims to describe the burden of pain during early intensive care after cardiac arrest and to evaluate associations between early pain burden and selected ICU and patient-reported outcomes. Pain is common in critically ill patients but may be difficult to assess in patients who are unconscious, sedated, mechanically ventilated, or unable to self-report. PAINCARE collects structured pain assessments during the first 168 hours after randomization using validated self-report or behavioral pain instruments and relates early pain burden to outcomes including delirium burden, ventilator-free time, ICU-free time, and follow-up pain outcomes. All analyses are observational; PAINCARE is not designed to determine whether modifying pain burden improves outcomes.",[419,420],"Pain","Out-of-hospital Cardiac Arrest (OHCA)",[422,423,424,425,426,427,428,429,430],"Chest compressions","delirium","quality of life","Cardiopulmonary resuscitation","Mechanical ventilation","ICU length of stay","critical care","cardiac arrest survivors","pain assessment","2026-05-11",{"date":433,"type":39},"2026-05-14",{"date":435,"type":39},"2023-10-15",{"date":437,"type":21},"2028-10-31",{"name":45,"class":46},3,{"id":441,"slug":442,"hasResults":12,"nctId":443,"briefTitle":444,"officialTitle":444,"acronym":445,"eligibilityCriteria":446,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":447,"targetDuration":4,"studyType":22,"phases":448,"briefSummary":450,"conditions":451,"keywords":453,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":431,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":152},"100553442","phase-3-egfr-mutated-lung-cancer-in-randomized-investigator-initiated-study-100553442","NCT06486142","EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study","ERIS","Inclusion Criteria:\n\n* The subject has given written consent to participate in the study.\n* Histological or cytological diagnosis of NSCLC.\n* Clinical stage III\u002FIV disease (with or without CNS metastasis) or a recurrence not amenable for curative treatment intention.\n* Measurable disease according to RECIST 1.1 criteria or equivalent\u002Fmodified criteria.\n* Any WHO PS.\n* Age ≥ 18 years, no upper age limit.\n* EGFR-mutation in tumor (in cases where tumor tissue is not available for mutation analysis, circulating tumor-DNA (ctDNA) in plasma may serve as inclusion criteria), which is presumably predictive of sensitivity to EGFR TKI.\n* Treatment-naive with regard to TKI's\n* Negative pregnancy test (blood or urine test)\n* For fertile participants, adequate contraception should be used; intrauterine device, bilateral tubal occlusion, vasectomy or abstinence (a reduced effect of hormonal contraception methods due to the drugs cannot be excluded). Pregnancy should be avoided during treatment and the first 4 months following treatment discontinuation.\n\nExclusion Criteria:\n\n* Condition incompatible with the study or with the planned treatment.\n* Present (not radically treated\u002Fno planned radical treatment of) other primary malignancy with metastatic potential.\n* Co-enrolment in other interventional trial if incompatible with ERIS according to investigator (e.g. due to potential drug interactions).\n* Intake of hypericum perforatum (intake must be interrupted before start of study treatment).\n* All subjects should avoid concomitant use of medications with known interaction with planned treatment, whenever feasible. If the administration of a medication interacts with any of the three investigational treatments and cannot be exchanged or managed in order to avoid interactions the patient is excluded from the trial.\n\n  * Drugs that can either increase or decrease the concentration of osimertinib in plasma:\n\n    * Strong activators of CYP3A. Simultaneous administration should be avoided.\n    * Regular CYP3A4-inhibitors should be used with caution or be avoided.\n  * Drugs that can either increase or decrease the concentration of afatinib in plasma:\n\n    * Strong inhibitors of P-glycoprotein should not be administered simultaneously with afatinib, instead it should preferably be 6-12 hours between.\n    * Strong activators of P-glycoprotein may reduce exposure of afatinib\n  * Drugs that can either increase or decrease the concentration of dacomitinib in plasma:\n\n    * Proton pump inhibitors should be avoided.\n    * Simultaneous administration of drugs that are metabolized by CYP2D6 should be avoided. If simultaneous use of that kind of medications are considered necessary, dose recommendations for simultaneous use of respective drug should be followed.\n* Any evidence of severe or uncontrolled systemic diseases which in the investigator's opinion makes it undesirable for the subject to participate in the trial or which would jeopardize compliance with the protocol. Screening for chronic conditions is not required.\n* Gastrointestinal conditions incompatible with swallowing or precluding absorption of the study drug.\n* Pregnancy or refusal to use contraceptives.\n* Abnormal findings of blood chemistry not compatible with the study drug according to investigator.\n* History of hypersensitivity to the study drug (or drugs with a similar chemical structure or class) or any excipients.\n* Severe hepatic impairment\u002Frenal function incompatible with study drug according to investigator.\n* Hereditary conditions with galactose intolerance, total lactase deficiency or glucose -galactose malabsorption.\n* Congenital long QT syndrome.\n* Judgment by the investigator that the subject should not participate in the study, e.g., if the subject is unlikely to comply with study procedures, restrictions and requirements.",{"count":370,"type":21},[449],"PHASE3","The purpose of this study is to evaluate the optimal sequence of EGFR-inhibitors in lung cancer patients with EGFR-positive tumors not amenable for curative treatment. Life quality, adverse effects and tumor response will be evaluated and analyses of obtained blood and tumor samples will be performed to identify molecular profiles and biomarkers that can be used for treatment decisions.",[452],"Non-Small Cell Lung Cancer",[454,455,456,457,458,459,460],"Non-small cell lung cancer","EGFR","Osimertinib","Afatinib","Dacomitinib","ctDNA","Resistance mechanisms",{"date":433,"type":39},{"date":463,"type":39},"2022-09-21",{"date":465,"type":21},"2028-09",{"name":45,"class":46},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":473,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":475,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":481,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":487,"lastUpdatePostDateStruct":488,"startDateStruct":489,"completionDateStruct":491,"leadSponsor":493,"locationsCount":494},"100488036","the-t-rex-trial-tailored-regional-external-beam-radiotherapy-in-clinically-node-negative-breast-cancer-patients-with-1-2-sentinel-node-macrometastases-100488036","NCT05634889","The T-REX Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases.","The T-REX-Trial: Tailored Regional External Beam Radiotherapy in Clinically Node-negative Breast Cancer Patients With 1-2 Sentinel Node Macrometastases; an Open, Multicenter, Randomized Non-inferiority Phase 3-trial.","T-REX","Inclusion Criteria:\n\n1. Primary unifocal or multifocal invasive breast cancer T1-T2.\n2. Clinically N0.\n3. Macrometastasis (\\>2mm) in 1-2 lymph nodes at sentinel node biopsy.\n4. Oral and written consent.\n5. Age ≥ 18 years.\n6. All resection margins are tumor free (no tumor on ink).\n7. Primary tumor ER-positive, HER2-negative.\n\nExclusion Criteria:\n\n1. Regional or distant metastases outside the ipsilateral axilla.\n2. Previous RT towards the planned target area, i.e. the ipsilateral chest\u002Flymph nodes.\n3. Neoadjuvant systemic therapy.\n4. Axillary lymph node dissection or other previous axillary surgery on the affected side.\n5. Prior history of invasive breast cancer.\n6. Pregnancy.\n7. Bilateral invasive breast cancer.\n8. Contraindication for radiotherapy or systemic treatment.\n9. Inability to absorb or understand the contents of the informed consent form; for example, through disability, inadequate language skills or dementia.\n10. Other invasive cancer within 5 years prior to breast cancer diagnosis",{"count":476,"type":21},1350,[24],"T-REX is a randomized multicenter, non-inferiority trial.\n\nAim: To evaluate whether regional radiotherapy may safely be omitted in clinically node negative breast cancer patients with one or two sentinel node macrometastases and an estrogen receptor positive, HER2-negative tumor. Leading to an improved quality of life and reduced side effects, without worsening recurrence free survival at five years.\n\nIntervention: Patients will be randomized to locoregional radiotherapy towards the breast\u002Fchestwall and regional lymph nodes vs. to a de-escalated radiotherapy.\n\nIn the intervention arm no lymph node irradiation will be given. Radiotherapy is still given to the remaining breast after breast conserving surgery, but no radiotherapy is given after mastectomy.\n\nSample size: 1350 patients\n\nPrimary end-point: Recurrence free survival at five years.\n\nGene expression analysis: For all patients gene expression analysis for the gene signatures ARTIC, POLAR and OncotypeDX will be performed and related to risk of recurrence and benefit of adjuvant radiotherapy.",[480],"Breast Cancer",[482,483,484,485,486],"breast cancer","radiotherapy","gene expression analysis","adjuvant breast cancer treatment","regional breast cancer treatment","2026-05-08",{"date":431,"type":39},{"date":490,"type":39},"2023-03-17",{"date":492,"type":21},"2033-12-31",{"name":45,"class":46},30,{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":501,"eligibilityCriteria":502,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":22,"phases":504,"briefSummary":505,"conditions":506,"keywords":508,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":511,"startDateStruct":512,"completionDateStruct":514,"leadSponsor":516,"locationsCount":152},"100619871","phase-4-combination-of-nerve-blocks-and-local-infiltration-analgesia-in-knee-arthroplasty-100619871","NCT07350252","Combination of Nerve Blocks and Local Infiltration Analgesia in Knee Arthroplasty","Postoperative Analgesia in Patients Undergoing Knee Replacement Surgery - a Study Comparing Intraoperative Local Infiltration Analgesia Only With Ultrasound-guided Nerve Blocks Added to Intraoperative Local Infiltration Analgesia, a Randomized Clinical Trial","BALIA","Inclusion Criteria:\n\n-Undergoing primary unilateral total knee arthroplasty\n\nExclusion Criteria:\n\n* Pregnancy\n* Coagulopathy or other bleeding disorder that precludes regional anesthesia\n* Allergy to local anesthetics\n* Inability to understand spoken and written Swedish\n* Unwillingness to participate in the study",{"count":370,"type":21},[216],"The aim of this clinical randomized trial is to compare local infiltration analgesia (LIA) alone versus the combination of LIA with saphenous nerve (SN) block, block of the nerve to vastus medialis (NVM), and anterior femoral cutaneous nerve (AFCN) block in participants undergoing total knee arthroplasty (TKA). The primary outcome is pain intensity, measured using the Numerical Rating Scale (NRS) at multiple time points after surgery. Secondary outcomes include opioid consumption, time to mobilization, postoperative nausea and vomiting, length of hospital stay, neurological complications and differences in opioid consumption and NRS pain scores between general and spinal anesthesia.",[507],"Osteo Arthritis of the Knee",[509],"Treatment","2026-05-04",{"date":487,"type":39},{"date":513,"type":39},"2026-03-05",{"date":515,"type":21},"2027-09-01",{"name":45,"class":46},{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":522,"acronym":523,"eligibilityCriteria":524,"healthyVolunteers":12,"sex":17,"minAge":525,"maxAge":526,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":529,"briefSummary":530,"conditions":531,"keywords":533,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":510,"lastUpdatePostDateStruct":539,"startDateStruct":541,"completionDateStruct":543,"leadSponsor":544,"locationsCount":545},"100564368","breath-holding-spells-and-its-management-study-100564368","NCT06628271","Breath-holding Spells and Its Management Study","Breath-holding Spells and Its Management: a Prospective Study on Patient and Disease Characteristics, Evaluation of Novel Guidelines, Parental Handling, and Long-term Follow-up in Breath-holding Spells","BAM","Inclusion Criteria:\n\n* Below 5 years of age\n* resident in Region Skåne (Sweden)\n* suspected breath-holding spell\n\nExclusion Criteria:\n\n* previous investigation for breath-holding spell (previous spells are not a reason for exclusion)","0 Months","60 Months",{"count":528,"type":21},120,[24],"The goal of this prospective population-based study is to evaluate the new disease description and management guidelines for breath-holding spells in children (Hellström Schmidt et al, Acta Paediatrica 2024) below the age of 5 years in southern Sweden. The main questions it aims to answer are:\n\n* Does the disease description and management guidelines lead to the expected reduction in diagnostic interventions and are the clinical managements guidelines safe to use?\n* If iron supplementation is given, does it reduce the frequency and severity of the spells?\n* What information and support does parents to children with breath-holding spells need?\n\nParticipants will undergo evaluation by a medical doctor and if typical breath-holding spells are diagnosed, be managed according to the new guidelines. If iron deficiency is found, iron supplementation is recommended. Digital surveys will be distributed and parents of patients with frequent spells will be eligible for participation in an interview sub-study.",[532],"Breath-holding Spell",[534,535,536,537,538],"disease definition","electrocardiography","iron deficiency anemia","long QT syndrome","parental support",{"date":540,"type":39},"2026-05-05",{"date":542,"type":39},"2024-12-02",{"date":203,"type":21},{"name":45,"class":46},12,{"id":547,"slug":548,"hasResults":12,"nctId":549,"briefTitle":550,"officialTitle":550,"acronym":551,"eligibilityCriteria":552,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":553,"enrollmentInfo":554,"targetDuration":416,"studyType":92,"phases":4,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":564,"completionDateStruct":566,"leadSponsor":568,"locationsCount":152},"100627222","evaluation-of-capsule-colonoscopy-in-patients-with-lynch-syndrome-100627222","NCT07445828","Evaluation of Capsule Colonoscopy in Patients With Lynch Syndrome","Lynch syndrome","Inclusion Criteria:\n\n* Genetically confirmed Lynch syndrome with a planned surveillance colonoscopy according to guideline-based recommendations\n* Age 18-60 years\n* Written informed consent obtained\n\nExclusion Criteria:\n\n* Need for an translator\n* Known history of gastroparesis or intestinal pseudo-obstruction\n* Known or suspected stricture or stenosis of the gastrointestinal tract\n* Previous small bowel or colonic resection\n* Dysphagia or swallowing difficulties\n* Severe debilitating disease\n* Allergy or contraindication to any medications or products used in the study\n* Pregnancy or breastfeeding","60 Years",{"count":555,"type":21},78,"Lynch syndrome is the most common hereditary cancer syndrome and is caused by pathogenic variants in DNA mismatch repair genes, resulting in a markedly increased lifetime risk of colorectal cancer. The estimated lifetime risk of colorectal cancer varies by the affected gene and is approximately 54-74% in men and 30-52% in women with Lynch syndrome. Colorectal cancer in this population is typically diagnosed at a younger age than in the general population. Current national guidelines recommend colonoscopic surveillance every one to two years beginning at 20-25 years of age to reduce colorectal cancer risk. However, individualized modification of surveillance strategies is under active consideration based on factors such as the specific mutated gene, family history of cancer, smoking status, prior malignancies, and age at surveillance initiation.\n\nConventional colonoscopy, the current standard method for colorectal evaluation, may cause substantial discomfort or anxiety, leading some patients to decline participation. Colonoscopy is also resource intensive, and procedural capacity is limited. Previously reported limitations in colonoscopy resources and quality in Sweden highlight the need to evaluate alternative surveillance and screening approaches.\n\nColon capsule endoscopy (CCE) has been available for clinical use since 2006 as a non-invasive alternative to colonoscopy, enabling endoscopic visualization of the entire colon. The system consists of a single-use, swallowable capsule containing miniature cameras that capture images as the capsule progresses through the gastrointestinal tract via natural peristalsis. Images are transmitted wirelessly to a portable data recorder worn by the patient and subsequently reviewed using dedicated software.\n\nCCE offers several advantages compared with conventional colonoscopy and CT colonography, including no requirement for sedation, endoscope insertion, gas insufflation, or ionizing radiation. The examination and image acquisition can be performed outside the hospital setting. This patient-centered approach has the potential to improve adherence to repeated examinations and long-term surveillance programs, which is particularly important for individuals with hereditary colorectal cancer syndromes. CCE may also reduce demands on healthcare resources.\n\nInternational guidelines indicate that the mucosal diagnostic performance of CCE is comparable to that of standard colonoscopy and that the method is appropriate for screening purposes. Adequate bowel preparation is required for both colonoscopy and CCE. Unlike conventional colonoscopy, bowel cleansing cannot be optimized during CCE, and the procedure is limited by capsule battery life, typically 10-12 hours. To maintain bowel cleanliness and facilitate capsule transit, patients administer laxative and prokinetic agents at predefined time points during the examination.\n\nThe primary objective of this study is to evaluate the diagnostic performance and safety of colon capsule endoscopy as a first-line surveillance modality in patients with Lynch syndrome and to assess patient experience and acceptance of CCE compared with conventional colonoscopy.",[558],"Lynch Syndrome",[558,560],"caspule colonoscopy","2026-04-29",{"date":563,"type":39},"2026-04-30",{"date":565,"type":21},"2026-05",{"date":567,"type":21},"2029-12-31",{"name":45,"class":46},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":575,"eligibilityCriteria":576,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":577,"enrollmentInfo":578,"targetDuration":4,"studyType":22,"phases":579,"briefSummary":580,"conditions":581,"keywords":583,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":4},"100621562","ssrd-and-overweight-100621562","NCT07372235","SSRD and Overweight","Comparison at Overweight Between Those Who Receive Feedback Concerning Their Metabolic Profile or Not During an Intervention With Modified Starch- and Sucrosereduced Diet (SSRD)","SSRD","Inclusion Criteria:\n\n* Ålder 18-70 år och språkkunskaper i svenska så att de kan tillgodogöra sig kostinformationen och ifylla formulären.\n* BMI ≥25 kg\u002Fm2\n\nExclusion Criteria:\n\n* Allvarlig födoämnesallergi\n* Allvarlig hjärt, lung, kardiovaskulär, magtarm, malign eller psykisk sjukdom\n* Pågående ätstörning\n* Graviditet\n* Står redan på en diet såsom vegan diet, regelbunden fasta \\>15 timmar per dag, eller låg kolhydrat hög fett (LCHF) diet de senaste 3 månaderna\n* Alkohol och\u002Feller drogberoende\n* Stora ändringar i kroppsvikt de senaste 3 månaderna (≥3 kg)\n* Står på viktreducerande läkemedel eller läkemedel som typ GLP-1 analoger","70 Years",{"count":415,"type":21},[24],"The investigators have previously found that a starch- and sucrosereduced diet (SSRD) has led decreased gastrointestinal symptoms in patients with irritabel bowel syndrome (IBS). At the same time, investigators found that the weight was reduced and the nutrient intake was improved with a more favorable metabolic profile. However, it is a challenge to change lifestyle, and most persons fail to keep on with an improved diet for a long time. Investigators therefore now want to conduct a clinical trial with SSRD in overweight\u002Fobesity for 3 months. Persons with a BMI \\>25 kg\u002Fm2 will be included. To examine whether a feedback about improved metabolic profile enhances the compliance, participants will be randomized to be informed or not about the metabolic profile after the 6-week visit. Investigator´s hypothesis is that information about the improvement in the metabolic profile should increase the motivation and compliance in the patients, and thereby render better effects.",[582],"Overweight (BMI > 25)",[584,575,585,586],"overweight","metabolomics","feedback on dietary efficiency","2026-04-28",{"date":561,"type":39},{"date":590,"type":21},"2026-09-01",{"date":592,"type":21},"2032-12-31",{"name":45,"class":46},{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":600,"eligibilityCriteria":601,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":577,"enrollmentInfo":602,"targetDuration":4,"studyType":22,"phases":604,"briefSummary":605,"conditions":606,"keywords":609,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":615,"startDateStruct":616,"completionDateStruct":618,"leadSponsor":620,"locationsCount":152},"100616745","sucrase-isomaltase-si-genes-and-meal-load-100616745","NCT07309601","Sucrase-Isomaltase (SI) Genes and Meal Load","Comparison of a Meal Load Between Normal and Functional Variants of the Sucrase-isomaltase (SI) Gene in IBS","SI IBS","Inclusion Criteria:\n\n* Diagnosis of irritable bowel syndrome (IBS)\n* Gene testing has been conducted regarding genes regulating the production of sucrase-isomaltase ensymes in previous dietary interventions using the starch- and sucrose reduced diet (SSRD) or multi-center study.\n\nExclusion Criteria:\n\n* Diagnosis of inflammatory bowel disease, celiac disease, bile salt malabsorption, gastroenteritis or enteric dysmotility\n* Severe food allergy\n* Serious heart-, lung-, cardiovascular-, malignant- or mental illness\n* Ongoing eating disorder\n* Pregnancy\n* Recent major gastrointestinal surgery\n* Alcohol and\u002For drug addiction",{"count":603,"type":21},70,[24],"The goal of this interventional study is to examine whether those patients with irritable bowel syndrome (IBS) and a reduced abitility do degrade starch and sugar (lowe levels of enzymes) have lower raise in blood glucose after a meal than those with normal expression of enzymes. We also want to examine whether those IBS patients with reduced enzyme levels have increased bowel symptom in relation to this meal.\n\nThe main questions it aims to answer are:\n\nDoes reduced ability to degrade starch and sugar due to less enzyme activity lead to lower increase in blood glucose after a meal? Does reduced ability to degrade starch and sugar due to less enzyme activity lead to increased bowel symptoms after a meal?",[607,608],"IBS - Irritable Bowel Syndrome","Sucrase-Isomaltase Deficiency",[610,611,612,613,614],"IBS","SI genes","Starch and sucrose","blood glucose levels","bowel symptoms",{"date":561,"type":39},{"date":617,"type":39},"2026-02-01",{"date":619,"type":21},"2030-02-01",{"name":45,"class":46},{"id":622,"slug":623,"hasResults":12,"nctId":624,"briefTitle":625,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":138,"enrollmentInfo":628,"targetDuration":4,"studyType":22,"phases":630,"briefSummary":631,"conditions":632,"keywords":635,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":639,"startDateStruct":640,"completionDateStruct":641,"leadSponsor":642,"locationsCount":152},"100622864","uneven-nutrition-and-life-style-as-ibd-triggers-in-adolescents-and-adults-100622864","NCT07389161","Uneven Nutrition and Life Style as IBD Triggers in Adolescents and Adults","UNITA","Inclusion Criteria:\n\n* IBD, i.e., Mb Crohn or ulcerrative colitis\n* Moderatively active disease (calprotectin 200-600)\n\nExclusion Criteria:\n\n* Proctitis alone\n* Inactive disease\n* Severe flare up requiring in-patient care\n* Planned change of treatment\n* Antibiotic treatment during the last month\n* Pregnancy\n* Inability to understand Swedish\n* Multimorbidity",{"count":629,"type":21},160,[24],"The aims of the study are 1. to determine the effect on dysbiosis, permeability and inflammatory activity after administration of a Mediterranean like diet (a Nordic equivalent, \"Nordiet\"), 2. to investigate life style related factors, such as exercise, psychosexual health and quality of life and their relation to the disease activity.",[633,634],"Mb Crohn","Ulcerative Colitis (UC)",[636,637,633,638],"Diet","Inflammatory bowel disease","Ulcerative colitis",{"date":561,"type":39},{"date":587,"type":39},{"date":567,"type":21},{"name":45,"class":46},{"id":644,"slug":645,"hasResults":12,"nctId":646,"briefTitle":647,"officialTitle":648,"acronym":649,"eligibilityCriteria":650,"healthyVolunteers":137,"sex":651,"minAge":18,"maxAge":4,"enrollmentInfo":652,"targetDuration":4,"studyType":22,"phases":653,"briefSummary":654,"conditions":655,"keywords":659,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":664,"startDateStruct":665,"completionDateStruct":667,"leadSponsor":669,"locationsCount":152},"100582004","clinical-explorative-optical-breast-investigations-100582004","NCT06857669","Clinical Explorative Optical Breast Investigations","Breast Cancer Diagnosis Using Optical Techniques","CLEO-B","Inclusion Criteria:\n\n* solitary malignant or benign biopsy verified tumour \\> 1 cm\n* understands written and oral Swedish\n\nExclusion Criteria:\n\n* previous breast surgery\n* has received neoadjuvant chemotherapy\n* skin burns in on the chest","FEMALE",{"count":5,"type":21},[24],"This study evaluates diffuse reflectance spectroscopy and photoacoustic imaging for differentiating healthy, benign, and malignant breast tissue by identifying their optical profiles.",[656,657,658],"Benign Breast Tumors","Malignant Breast Tumours","Healthy",[660,661,662,663],"breast","optical imaging","photoacoustic","spectroscopy",{"date":561,"type":39},{"date":666,"type":39},"2020-12-01",{"date":668,"type":21},"2027-05-30",{"name":45,"class":46},{"id":671,"slug":672,"hasResults":12,"nctId":673,"briefTitle":674,"officialTitle":675,"acronym":676,"eligibilityCriteria":677,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":678,"targetDuration":4,"studyType":22,"phases":680,"briefSummary":681,"conditions":682,"keywords":686,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":689,"startDateStruct":690,"completionDateStruct":692,"leadSponsor":694,"locationsCount":152},"100577629","prolonged-chest-tube-treatment-to-reduce-rates-of-atrial-fibrillation-following-cardiac-surgery-100577629","NCT06800781","Prolonged Chest Tube Treatment to Reduce Rates of Atrial Fibrillation Following Cardiac Surgery","Prolonged Posterior Pericardial Chest Tube Treatment to Reduce Rates of Postoperative Atrial Fibrillation Following Cardiac Surgery","PROPER","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Undergoing non-emergent surgery (\\>24 hours between decision to operate and surgical procedure) with coronary artery bypass grafting, aortic valve replacement, aortic surgery without the use of circulatory arrest, or any combination of these procedures\n* Able to give written informed consent\n\nExclusion Criteria:\n\n* History of atrial fibrillation (AF) or atrial flutter\n* History of electrophysiological interventions or treatment with antiarrhythmic drugs due to arrhythmias other than AF\n* Pre- or postoperative prophylactic treatment with amiodarone\n* Existing pacemaker, ICD, or CRT device without a functional atrial lead\n* Aortic surgery with hypothermic circulatory arrest\n* Previous cardiac surgery\n* Previous radiation of the chest due to malignancy\n* Ongoing infection at time of surgery\n* Ongoing treatment with immunosuppressants, including oral corticosteroids\n* Patient already included in another interventional clinical trial\n* Patient listed abroad, which would render them to be lost to follow-up after discharge\n* Patient does not understand study information given in the local language or, for other reasons, is deemed unfit to participate according to the investigators.",{"count":679,"type":21},624,[24],"Evacuation of pericardial blood by posterior pericardiotomy or use of a posterior pericardial chest tube lowers postoperative atrial fibrillation (POAF) rates after cardiac surgery by 45-68%. Although it cannot be generalized due to trial undersizing, posterior pericardial chest tube treatment may be a superior alternative to pericardiotomy, given its low risk of procedural complications.\n\nThis interventional multicenter trial will assess whether prolonged treatment with a posterior pericardial chest tube lowers POAF rates after cardiac surgery. Investigators will randomize 624 patients undergoing routine cardiac surgery at Nordic sites 1:1 to receive a posterior pericardial chest tube as adjunct to standard care for up to 3 postoperative days or standard care alone. The primary outcome is the proportion of patients with POAF up to 7 days post-surgery; the study will be powered to detect a relative risk reduction of 30% in the intervention arm. Secondary outcomes are AF burden; days with chest tubes and their output; proportion of patients with POAF up to 14 days post-surgery; direct current conversions during hospital admission; length of ICU\u002Fhospital stay; postoperative complications, mortality, ischemic stroke, and major bleeding at 30\u002F90 days and 1\u002F3\u002F5 years; and quality of life\u002Fpostoperative recovery at 90 days and 1 year. This trial may provide quality clinical evidence supporting the adoption of a simple method to prevent POAF, thus reducing healthcare costs.",[683,684,685],"Coronary Arterial Disease (CAD)","Valve Replacement","Aortic Surgery",[687,688],"Posterior pericardial chest tube","Postoperative atrial fibrillation (POAF)",{"date":561,"type":39},{"date":691,"type":39},"2025-02-10",{"date":693,"type":21},"2033-12",{"name":45,"class":46},""]